Immunotherapy combo shows promise against sarcoma in early trial
NCT ID NCT04968106
First seen Apr 26, 2026
Summary
This phase 2 trial tests whether adding the immunotherapy drug retifanlimab to standard chemotherapy before surgery can improve outcomes for people with resectable soft-tissue sarcoma. About 66 participants will receive either chemotherapy alone or chemotherapy plus retifanlimab. The main goal is to see if the combination leads to a better tumor response in the surgical sample.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Léon Bérard
Lyon, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Curie
Paris, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Retifanlimab (a drug that helps the immune system fight cancer) plus chemotherapy (doxorubicin and ifosfamide)
What this could lead to
If successful, this could lead to a new treatment option that improves tumor shrinkage before surgery and delays sarcoma recurrence.
What could go wrong
This is an early-phase trial with only 66 participants, so results may not apply to all sarcoma patients. Adding immunotherapy to chemotherapy can increase side effects like immune-related inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.